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Abstract
This Article examines the preliminary injunction standard in pharmaceutical patent infringement
actions pursuant to the Hatch-Waxman Act. Prior to
Supreme Court’s decision in eBay v. MercExchange,
L.L.C. in 2006, federal courts applied a presumption
of irreparable harm when a patent holder established
a likelihood of success on the merits. While the eBay
Court abrogated the presumption of irreparable
harm in permanent injunctions, courts have been
unclear as to application of eBay on preliminary injunctions. This Article will further examine preliminary injunctions in Hatch-Waxman actions in the
District of New Jersey since eBay in 2006 and argue
that courts still tacitly apply the irreparable harm
presumption.
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INTRODUCTION
In 2010, sales of prescription drugs in the
United States totaled over $300 billion.1 In the same
year, sales of generic drugs were valued at $78 billion.2 Six of the world’s ten largest pharmaceutical
companies are based in the United States. 3 Approximately eighty percent of the world’s research in biotechnology and pharmaceuticals are conducted by

1 Brittany Hart, Pharmaceutical Sales Top $300 Billion in
2010, DAYTON BUS. J. (Apr. 19, 2011, 2:58 PM),
http://www.bizjournals.com/dayton/news/2011/04/19/pharmaceu
tical-sales-top-300-billion.html.
2 The Pharmaceutical Industry in the United States,
SELECTUSA, http://selectusa.commerce.gov/industrysnapshots/pharmaceutical-industry-united-states (last visited
Feb. 5, 2014).
3 Pharmaceutical Industry, WORLD HEALTH ORG.,
http://www.who.int/trade/glossary/story073/en/index.html (last
visited Feb. 5, 2014).
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American pharmaceutical companies.4
In other
words, the drug business is big business in America.
The pharmaceutical industry can be roughly
divided into two categories; brand name manufacturers, also called “innovator companies,” and generic
manufacturers.5 Generic drugs are bioequivalent 6
versions of brand name medication and present significant savings to consumers.7 The development
cost of a generic drug is much lower in comparison to
that of a brand name drug.8 The process of research
and clinical trials for a new drug usually takes ten to
fifteen years and can cost an innovator company upwards of $800 million.9 Brand name medications are
protected by patents and the process in which generic drugs enter the market is governed by the
Hatch-Waxman Act.10
The Hatch-Waxman Act was passed with the
4 The Pharmaceutical Industry in the United States, supra
note 2.
5 See Greater Access to Generic Drugs, U.S. FOOD & DRUG
ADMIN.,
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm14354
5.htm (last visited Feb. 5, 2014).
6 Christopher J. Kochevar, Note, Reforming Judicial Review
of Bioequivalence Determinations, 87 N.Y.U. L. REV. 2040, 2042
(2012) (“‘[B]ioequivalence’ [is] an approximation of identity
between a generic drug and an approved innovator product.”).
7 Greater Access to Generic Drugs, supra note 5. (“[T]he
average price for a prescription for a brand-name drug is
$84.20, while the average price for a generic drug prescription
is $30.56.”).
8 Wansheng Jerry Liu, Balancing Accessibility and
Sustainability: How to Achieve the Dual Objectives of the HatchWaxman Act While Resolving Antitrust Issues in
Pharmaceutical Patent Settlement Cases, 18 ALB. L.J. SC. &
TECH. 441, 447 (2008).
9 Id. at 482.
10 Greater Access to Generic Drugs, supra note 5.
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intention to give innovator companies additional incentives to develop new drugs while giving the
American consumer savings by expanding the generics market.11 Since the enactment of the HatchWaxman Act, the market share held by generic drugs
has increased from under twenty percent in 1984 to
nearly eighty percent in 2010.12
This Article will discuss the preliminary injunction factors as applied when an innovator company seeks to enjoin a generic maker from releasing
a competing product during the course of litigation
under the Hatch-Waxman Act. Specifically, this Article will argue that the presumption of irreparable
harm, which was abrogated by the Supreme Court in
eBay, Inc. v. MercExchange, L.L.C., still exists even if
the presumption is not explicitly applied. Part I will
briefly discuss Federal jurisdiction in patent matters.
Part II will discuss the four preliminary injunction
factors and its development in patent law, including
eBay and its subsequent line of cases. Part III will
explain the historical context which led to the passage of the Hatch-Waxman Act and discuss in detail
the process by which a generic drug is approved for
market. Part IV will be a survey of pharmaceutical
patent cases before the District of New Jersey since
the eBay decision in 2006. This Article will conclude
by arguing that the presumption of harm still exists,13 how a tacit application of the presumption is
permissible under current law, and propose that
See infra Part III.B.
Liu, supra note 8, at 456; Karen von Koeckritz, Generic
Drug Trends –What’s Next?, PHARMACY TIMES (Apr. 11, 2012),
http://www.pharmacytimes.com/publications/issue/2012/April20
12/Generic-Drug-Trends-Whats-Next-.
13 This Article will only discuss the presumption of harm as it
exists within the District of New Jersey.
11
12
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Congress amend the Hatch-Waxman Act to allow for
the presumption of harm in preliminary injunction
determinations.
I. FEDERAL JURISDICTION IN PATENT MATTERS
Federal courts have original and exclusive jurisdiction in all matters “arising under any Act of
Congress relating patents, . . . copyrights and trademarks.”14 Patents have been within the ambit of
Federal jurisdiction since the earliest days of the
Republic.15 In 1982, Congress created the United
States Court of Appeals for the Federal Circuit as
one of the provisions of the Federal Courts Improvement Act.16 The legislation gave the Federal Circuit
exclusive jurisdiction over appeals from the district
courts in patent cases.17 As a result, the new Federal
Circuit’s jurisdiction in patent matters was much
broader than that of one of the courts it replaced, the
United States Court of Customs and Patent Appeals
(CCPA).18 Previously, the CCPA only had jurisdic28 U.S.C. § 1338(a) (2012).
See U.S. CONST. art. I, § 8; see also 8 DONALD S. CHISUM,
CHISUM ON PATENTS § 21.02(1)(a)(i) (2013) (“Section 17 of the
Patent Act of 1836 conferred jurisdiction without regard to
amount over ‘all actions, suits, controversies, and cases arising
under any law of the United States, granting or confirming to
inventors the exclusive right to their inventions or
discoveries.’”).
16 Federal Courts Improvement Act of 1982, Pub. L. No. 97164, 96 Stat. 25 (codified as amended in scattered sections of 28
U.S.C.).
17 28 U.S.C. § 1295(a)(1) (2012); see also Joseph R. Re, Brief
Overview of the Jurisdiction of the U.S. Court of Appeals for the
Federal Circuit Under § 1295(a)(1), 11 FED. CIR. B.J. 651, 654
(2001).
18 AM. BAR ASS’N, REPORT ON THE UNITED STATES COURT OF
APPEALS FOR THE FEDERAL CIRCUIT 6-7 (2002), available at
14
15
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tion over appeals from the United States Patent and
Trademark Office.19 Prior to the creation of the Federal Circuit, patent suits filed in the district courts
were appealed to the regional circuit courts.20 Currently, circuit splits do not exist in patent law because all patent appeals are reviewed by the Federal
Circuit.21
II. THE PRELIMINARY INJUNCTION STANDARD:
PAST AND PRESENT
Congress has given courts power to “grant injunctions in accordance to the principles of equity” in
patent cases.22 Courts use the traditional four equitable factors to determine whether a preliminary injunction is proper.23
The first factor, likelihood of success on the
merits, undergoes a two-step analysis in patent in-

http://www.morganlewis.com/pubs/2951F5BA-25A3-457DB4B2CA99691EE6F1_Publication.pdf.
19 Id.
20 See, e.g., Eli Lilly & Co. v. Premo Pharm. Labs., Inc., 630
F.2d 120 (3d Cir. 1980).
21 Cf. Erin V. Klewin, Note, Reconciling Federal Circuit
Choice of Law with eBay v. MercExchange’s Abrogation of the
Presumption of Irreparable Harm in Copyright Preliminary
Injunctions, 80 FORDHAM L. REV. 2113, 2118-23 (2012) (noting
that in copyright matters, also affected by the holding in eBay,
the Federal Circuit only has jurisdiction in pendant matters
and applies regional circuit law in those cases).
22 35 U.S.C. § 283 (2012).
23 Amazon.com, Inc. v. Barnesandnoble.com, Inc., 239 F.3d
1343, 1350 (Fed. Cir. 2001) (citing Reebok Int’l Ltd. v. J. Baker,
Inc., 32 F.3d 1552, 1555 (Fed. Cir. 1994)) (“(1) a reasonable
likelihood of success on the merits; (2) irreparable harm if an
injunction is not granted; (3) a balance of hardships tipping in
its favor; and (4) the injunction’s favorable impact on the public
interest.”).
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fringement cases.24 The plaintiff must establish that
the defendant has infringed on the patent. 25 First,
the court determines the scope of the patent claims. 26
Then, the allegedly infringing product is compared to
see if it lies within the scope of the patent. 27 Under
the doctrine of equivalents, a product may still be infringing if it performs in the same manner to achieve
the same results as the original invention.28
Further, the plaintiff must also establish that
the patent can withstand the defendant’s claim of invalidity.29 Typically, defendants allege that the patented product is obvious, meaning the patent is invalid under 35 U.S.C. § 103(a). 30 Courts employ a
four factor analysis in determining obviousness.31
The courts have also acknowledged that new inven-

24 Tate Access Floors, Inc. v. Interface Arch. Resources, Inc.,
279 F.3d 1357, 1365 (Fed. Cir. 2002) (citing Amazon.com, 239
F.3d at 1351).
25 Id.
26 Aventis Pharm., Inc. v. Barr Labs., Inc., 411 F.Supp.2d 490,
494 (D.N.J. 2006) (quoting Amazon.com, 239 F.3d at 1351).
27 Id.
28 Syntex Pharm. Int’l, Ltd. v. K-Line Pharm., Ltd., 721
F.Supp. 653, 660-61 (D.N.J. 1989) (citing Graver Tank & Mfg.
Co. v. Linde Air Prods. Co., 339 U.S. 605, 608 (1950)).
29 See Tate, 279 F.3d at 1365 (citing Hybritech, Inc. v. Abbott
Labs., 849 F.2d 1446, 1451).
30 Altana Pharma AG v. Teva Pharm. USA, Inc., 532
F.Supp.2d 666, 674 (D.N.J. 2007) aff’g, 566 F.3d 399 (Fed. Cir.
2009); see also 35 U.S.C. § 103(a) (2012).
31 Id. (citing PharmaStem Therapeutics, Inc. v. Viacell, Inc.,
491 F.3d 1342, 1359 (Fed. Cir. 2007)) (“Factual determinations
that are relevant to the obviousness inquiry are: (1) the scope
and content of the prior art; (2) the differences between the
claimed invention and the prior art; (3) the level of ordinary
skill in the art; and (4) secondary considerations or objective
indicia of non-obviousness.”).
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tions are often built upon prior innovations. 32 The
Supreme Court has, on occasion, upheld patents comprised of knowledge of prior patents when the new
patent aimed to solve a problem previously not apparent.33
The second factor, irreparable harm, also
called irreparable injury, is defined as “[a]n injury
that cannot be adequately measured or compensated
by money.”34 In other words, an injury is irreparable
if money damages at the conclusion of a trial are insufficient to make the plaintiff whole. 35 Professor
Donald Chisum notes that courts have been inconsistent in irreparable harm determinations and “tend
to find irreparable injury when the plaintiff makes a
strong case of validity and infringement and to find
no such injury when plaintiff makes only a weak
case.”36 This inconsistency will be discussed in depth
further in this Article.37
The balance of hardships generally weighs in
favor of the innovator company in Hatch-Waxman
litigation. When a generic is released, the innovator
company suffers harm through price erosion and loss
of market share.38 Courts have been reluctant to
weigh the factor in favor of defendants since any loss
suffered by a generic maker incurred during the duration of the suit would simply be sales “time-

32 Id. (citing KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398, 41820 (2007)).
33 Id. (citing KSR, 550 U.S. at 419).
34 BLACK’S LAW DICTIONARY 856 (9th ed. 2009).
35 7 CHISUM, supra note 15, at § 20.04(1)(e).
36 Id.
37 See infra Part IV.
38 See infra text accompanying notes 153-54.
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shifted” into the future.39 Thus, the balance of hardships rarely weigh in favor of the generic maker.40
Likewise, in Hatch-Waxman litigation, the
public interest will generally weigh in favor of the
plaintiff.41 Innovator companies often advance the
argument that the public interest is served when the
patent rights are enforced to exclude generic makers
during the patent’s term of exclusivity. 42 Further,
they also argue that profits generated during the exclusivity period fund research benefiting newer
medications.43 Generic makers will often argue that
the public interest is best served when the public has
access to lower cost medication.44 However, the Federal Circuit has been clear that the enforcement of
patent rights outweighs the public’s access to more
affordable medication.45
39 Albany Molecular Research, Inc. v. Dr. Reddy’s Labs., Inc.,
No. 09-4638 (GEB-MCA), 2010 WL 2516465, at *11 (D.N.J.
June 14, 2010).
40 King Pharm., Inc. v. Sandoz, Inc., No. 08-5973 (GEB-DEA),
2010 WL 1957640, at *1, 6 (D.N.J. May 17, 2010) (explaining
that when a prior TRO enjoining the defendant from releasing a
generic was dissolved when the plaintiff’s authorized generic
maker released their version early, the court weighed the
balance of the hardships in favor neutrally because the
defendant’s exclusivity period as the first generic maker under
the Hatch-Waxman Act had been encroached upon, and denied
the preliminary injunction).
41 See, e.g., Pfizer, Inc. v. Teva Pharm. USA, Inc., 429 F.3d
1364, 1382 (Fed. Cir. 2005) (The Hatch-Waxman Act does not
“encourage or excuse the infringement of infringing valid
pharmaceutical patents.”).
42 Novartis Pharm. Corp. v. Teva Pharm. USA, Inc. (Novartis
I), No. 05-CV-1887 (DMC), 2007 WL 2669338, at *15 (D.N.J.
Sept. 6, 2007).
43 Id.
44 Id.
45 Pfizer, Inc. v. Teva Pharm. USA, Inc., 429 F.3d 1364, 1382
(Fed. Cir. 2005) (quoting Payless Shoesource, Inc. v. Reebok
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A. The Presumption of Irreparable
Harm Prior to eBay
Soon after its establishment, the Federal Circuit held that a plaintiff is entitled to a presumption
of irreparable harm when it establishes a likelihood
success on the merits.46 The court further elaborated
in a subsequent case that the presumption is derived
“in part from the finite term of the patent grant, for
patent expiration is not suspended during litigation.”47 The value of the patent is based on exclusivity and monetary damages are insufficient to make
up for lost exclusivity.48
However, the Federal Circuit also held that
presumption of irreparable harm was a rebuttable
presumption.49 The Reebok case illustrates an instance when the presumption of irreparable harm
was rebutted through evidence.50 In November 1992,
Reebok began manufacturing and selling the SHAQ I
shoe and heavily promoted the shoe with basketball
great Shaquille O’Neal.51 Over a year later in December 1993, a patent was issued protecting the design of the shoe.52 As soon as the patent was issued,
Reebok served a complaint on J. Baker alleging that
their Olympian shoe infringed on the design of the
Int’l, Ltd., 998 F.2d 985, 991 (Fed. Cir. 1993)) (“Selling a lower
priced product does not justify infringing a patent.”).
46 7 CHISUM, supra note 15, at § 20.04(1)(c)(iii)(e)(i) (citing
Smith Int’l, Inc. v. Hughes Tool Corp., 718, F.2d 1573 (Fed. Cir.
1983)).
47 Id. (quoting H.H. Robertson Co. v. United Steel Deck, Inc.,
820 F.2d 384, 390 (Fed. Cir. 1987)).
48 Id.
49 Id. (quoting Ill. Tool Works, Inc. v. Grip-Pak, Inc., 906 F.2d
679, 681 (Fed. Cir. 1990)).
50 Reebok Int’l v. J. Baker, Inc., 32 F.3d 1552 (Fed. Cir. 1994).
51 Id. at 1554.
52 Id.
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SHAQ I.53 J. Baker had been manufacturing and
selling the Olympian shoe since July 1993. 54
The district court denied Reebok’s motion to
enjoin J. Baker from selling their remaining inventory of the Olympians.55 The Federal Circuit affirmed the district court’s decision because J. Baker
presented sufficient evidence to rebut the presumption that Reebok would suffer irreparable harm. 56 J.
Baker had established that Reebok had discontinued
the SHAQ I in favor a newer shoe, the SHAQ II. 57
The court reasoned that future purchasers of the
Olympians “would not likely confuse that shoe” with
the SHAQ I because Reebok had ceased all manufacture and promotion of the shoe.58 Because J. Baker
only had a limited supply of the Olympians, any
harm Reebok would have suffered could be sufficiently compensated by money damages.59 Thus, J.
Baker was successful in rebutting Reebok’s presumption of harm and the district court properly denied a
preliminary injunction to Reebok.60 However, Reebok is the exception rather than the rule; plaintiffs
who establish a likelihood of success on the merits
often succeed in enjoining the infringing party. 61
B. eBay, Inc. v. MercExchange, L.L.C.
It is commonly understood that the holding in
Id.
Id.
55 Id.
56 Id. at 1558.
57 Id.
58 Id.
59 Id.
60 Id. at 1559.
61 See supra text accompanying note 36; see also discussion
infra Part IV.
53
54
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eBay eliminated the presumption of irreparable
harm in preliminary injunction determinations. 62
However, the issue before the Supreme Court in
eBay was a permanent injunction and neither preliminary injunctions nor the presumption of irreparable harm were explicitly mentioned.63
MercExchange patented a process that “facilitate[d] the sale of goods between private individuals
by establishing a central authority to promote trust
among participants” in an online marketplace. 64
eBay and Half.com, its subsidiary, had been negotiating with MercExchange to purchase its technology
but the talks broke down.65 After the cessation of the
negotiations, MercExchange filed a patent infringement suit against eBay.66
A jury found at trial that MercExchange’s patent was valid, eBay had infringed on their patent,
and awarded damages to the plaintiff. 67 However,
the district court denied permanent injunctive relief
to MercExchange.68 The Federal Circuit reversed,
citing to its general rule that courts will issue a per62 See, e.g., Ortho McNeil Pharm., Inc. v. Barr Labs., Inc., No.
03-4678 (SRC), 2009 WL 2182665, at *9 (D.N.J. July 22, 2009)
(“[T]he Court is of the view that the presumption of irreparable
harm did not survive the Supreme Court’s decision in [eB]ay.”)
(citation omitted); Klewin, supra note 21, at 2129-30.
63 eBay, Inc. v. MercExchange, L.L.C., 547 U.S. 388, 390
(2006).
64 Id.
65 Id.
66 Id.; Miranda Jones, Note, Permanent Injunction, a Remedy
by Any Other Name is Patently Not the Same: How eBay v.
MercExchange Affects the Patent Right of Non-Practicing
Entites, 14 GEO. MASON L. REV. 1035, 1054-55 (2007)
(explaining the dispute arose from MercExchange alleging that
eBay’s “Buy it Now” feature infringed their patents).
67 eBay, 547 U.S. at 390-91.
68 Id.
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manent injunction “once infringement and validity
have been adjudged.”69
Justice Thomas enunciated that courts should
not depart from traditional notions of equity without
legislative authorization.70 Justice Thomas further
cited to specific language in 35 U.S.C. § 283 revealing
the legislative intent not to stray from equitable
principles.71 Having rejected the Federal Circuit’s
general rule favoring permanent injunctions, the
case was remanded for proceedings consistent with
the traditional four part analysis for injunctive relief.72 When the matter was remanded to the lower
courts eBay refused to settle.73 By 2008, eBay had
purchased the patent and related technologies from
MercExchange.74
C. Confusion and Clarity After eBay
The Supreme Court was not clear as to whether its holding in eBay applied to the irreparable harm
presumption in preliminary injunctions.75 The Federal Circuit did not bring clarity when it sidestepped
69 Id. at 393-94 (quoting MercExchange, L.L.C. v. eBay, Inc.,
401 F.3d 1323, 1338 (Fed. Cir. 2005)) (internal quotations
omitted).
70 Id. at 391-92.
71 Id.
72 Id. at 394.
73 Ina Steiner, eBay v MercExchange Patent War: It’s Over,
ECOMMERCEBYTES.COM (Feb. 28, 2008),
http://www.ecommercebytes.com/cab/abn/y08/m02/i28/s00.
74 Id.
75 eBay, 547 U.S. at 394 (“We hold only that the decision
whether to grant or deny injunctive relief rests within the
equitable discretion of the district courts, and that such
discretion must be exercised consistent with traditional
principles of equity, in patent disputes no less than in other
cases governed by such standards.”).
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the irreparable harm presumption in one of its first
patent decisions post-eBay.76 In Abbott, the court vacated a preliminary injunction and reversed the district court’s irreparable harm determination.77 The
court reasoned that Abbott was not entitled to a finding of irreparable harm on the basis that Abbott
failed to establish the first factor. 78 While acknowledging the holding of eBay, the Federal Circuit was
not clear as to the survival of the irreparable harm
presumption.79 Without offering additional reasons
as to why Abbott was denied a finding of irreparable
harm, the Federal Circuit did not fully decouple the
first two preliminary injunction factors.80
The Federal Circuit sidestepped the presumption of harm issue for a second time in SanofiSynthelabo v. Apotex, Inc.81 Apotex argued that the
trial court erred in applying the presumption of irreparable harm contrary to the holding in eBay.82
The Federal Circuit reasoned that Sanofi had established irreparable harm and declined to rule on the
76 See Abbott Labs. v. Andrx Pharm., Inc., 452 F.3d 1331 (Fed.
Cir. 2006).
77 Id. at 1347-48.
78 Id. at 1347.
79 Id. (“[W]e conclude that Abbott has not established a
likelihood of success on the merits. As a result, Abbott is no
longer entitled to a presumption of irreparable harm.”)
(emphasis added).
80 See id.
81 Sanofi-Synthelabo v. Apotex, Inc., 470 F.3d 1368 (Fed. Cir.
2006).
82 Id. at 1383, n.9 (“Apotex contends that applying such a
presumption is in direct contravention of the Supreme Court’s
decision in eBay Inc. v. MercExchange, L.L.C. Because we
conclude that the district court did not clearly err in finding
that Sanofi established several kinds of irreparable harm,
including irreversible price erosion, we need not address this
contention.”) (citations omitted).
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presumption.83 In 2008, Federal Circuit declined to
rule on presumption of harm for the third time in
Amado v. Microsoft Corporation stating it was unnecessary for the court to make a definitive ruling on
the issue.84
The lack of a clear ruling from the Federal Circuit led to confusion among the district courts.85
Some courts continued to apply the presumption of
harm noting that eBay only applied to permanent injunctions.86 Others ruled that eBay had eliminated
the presumption.87 There is even an instance where
a court ruled that eBay had eliminated the presumption but declined to apply the presumption only because the plaintiff failed to establish success on the
merits.88
In 2011, the Federal Circuit finally announced
Id.
Amado v. Microsoft Corp., 517 F.3d 1353, 1359 n.1 (Fed.
Cir. 2008) (“We find it unnecessary to reach this argument,
however, because regardless of whether there remains a
rebuttable presumption of irreparable harm following eBay, the
district court was within its discretion to find an absence of
irreparable harm based on the evidence presented at trial.”)
(emphasis added).
85 See, e.g., Everett Labs., Inc. v. Breckenridge Pharm., Inc.,
573 F.Supp.2d 855, 866 (D.N.J. 2008) (“In the wake of [the
eBay] decision, the Federal Circuit has neither overruled its
cases applying the presumption of irreparable harm nor offered
an explicit directive on whether (1) to apply the presumption on
a motion for a preliminary injunction or (2) the presumption
exists at all.”).
86 See, e.g., Abbott Labs.v. Andrx Pharm., Inc. 452 F.3d 1331,
1347-48 (Fed. Cir. 2006).
87 See, e.g., Ortho McNeil Pharm., Inc. v. Barr Labs., Inc., No.
03-4678 (SRC), 2009 WL 2182665, at *9 (D.N.J. July 22, 2009).
88 Klewin, supra note 21, at 2136 (citing Wireless TV Studios,
Inc. v. Digital Dispatch Systems, Inc., No. 07 CV 5103, 2008 WL
2474626, at *3 (E.D.N.Y. June 19, 2008)).
83
84
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that “eBay jettisoned the presumption of irreparable
harm as it applies to determining the appropriateness of [preliminary] injunctive relief.”89 However, in
the absence of the presumption, courts can still reach
similar results by examining the patent holder’s
right to exclude. 90 In “traditional” cases of patent infringement where both the patentee and infringer
are manufacturing or using the technology courts are
more likely to find irreparable harm.91 This is in
contrast to “non-traditional” cases like eBay where
the patentee had not made a commercial use of the
patent.92
III. THE HATCH-WAXMAN ACT AND
PHARMACEUTICAL PATENT ACTIONS
The Hatch-Waxman Act93 was enacted to
achieve two competing goals: protecting pharmaceutical patent rights and encouraging competition from
generic pharmaceutical makers.94 This Part will describe historical background the Act, the provisions
of the Act, and the process outlined in the Act for the
approval of generic pharmaceuticals.

89 Robert Bosch LLC v. Pylon Mfg. Corp., 659 F.3d 1142, 1149
(Fed. Cir. 2011).
90 Id.
91 Id. at 1150-51.
92 Id. at 1150 (citing eBay v. MercExchange, L.L.C., 547 U.S.
388, 396-97 (Kennedy, J., concurring)).
93 Drug Price Competition and Patent Term Restoration Act of
1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in
scattered sections of 15, 21, 35, and 42 U.S.C.).
94 Elizabeth Stotland Weiswasser & Scott D. Danzis, The
Hatch-Waxman Act: History, Structure, and Legacy, 71
ANTITRUST L.J. 585, 590 (2003).
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A. Pharmaceutical Approvals Prior to the
Hatch-Waxman Act
The Food and Drug Administration (FDA) was
empowered by the Federal Food, Drug, and Cosmetic
Act (FDCA) in 1938 to keep unsafe drugs from the
market by reviewing all new drugs prior to market
entry.95 Under this Act, before a new drug was permitted to enter the market the manufacturer was required to submit a new drug application (NDA). 96
The NDA contained scientific studies attesting to the
drug’s safety.97
The FDA maintained a policy that kept any
unpublished information submitted with an NDA as
confidential.98 It reasoned that if competitors had
access to the information contained in the NDA, they
could use the information as a shortcut in their own
NDA submittals.99 The FDA further reasoned that
competing companies making identical or similar
drugs would be less likely to invest in testing and
safety practices if they could demonstrate the safety
of their own products through the research of another drug maker.100 The policies promulgated by
the FDA at the time presented a barrier to generic
makers.101
In 1962, the FDCA was amended to require
drug makers to establish the effectiveness of their
drugs in the NDA process in addition to the prior re95 Id. at 587; see also Federal Food, Drug, and Cosmetic Act of
1938, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as
amended at 21 U.S.C. §§ 301-99f).
96 Weiswasser & Danzis, supra note 94, at 587.
97 Id.
98 Id.
99 Id.
100 Id.
101 See id.
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quirements.102 Over time, drug makers were often
required to run at least two clinical trials in order to
“demonstrat[e] statistically significant benefits for
consumers.”103 Drug makers were often required to
file for a patent before clinical trials.104 The new requirements burdened the drug makers with lengthy
studies and trials which eroded the exclusivity periods of their patents.105
In 1970, the FDA created the Abbreviated
New Drug Application (ANDA), an approval process
for generic drugs.106 However, there were relatively
few generic drugs on the market because the ANDA
process primarily applied to generic versions of drugs
approved prior to 1962.107 Despite streamlining the
ANDA process even further in 1980, there was very
little generic competition in the market.108
There was great concern over the rise of prescription drug prices in the early 1980s. 109 Drug
makers, without competition from generic makers,
were able to charge high prices to recoup the immense cost of the FDA application process in the
short period of effective exclusivity.110 The need to
Id. at 588.
Id.
104 Pamela J. Clements, The Hatch-Waxman Act and the
Conflict Between Antitrust Law & Patent Law, 48 IDEA 381,
386 (2008).
105 Id. (noting that in some instances, drug makers lost “up to
ten years” of exclusivity).
106 Weiswasser & Danzis, supra note 94, at 589.
107 Id.
108 Id. at 590.
109 Id.
110 See B. Scott Eidson, Note, How Safe is the Harbor?
Considering the Economic Implications of Patent Infringement
in Section 271(e)(1) Analysis, 82 WASH. U. L.Q. 1169, 1172
(2004).
102
103
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reduce drug prices through competition while increasing incentives for innovation set the stage for
the Hatch-Waxman Act.
B. The Hatch-Waxman Act
The Hatch-Waxman Act was enacted with the
intention “to balance two conflicting policy objectives:
to induce name brand pharmaceutical firms to make
the investments necessary to research and develop
new drug products, while simultaneously enabling
competitors to bring cheaper, generic copies of those
drugs to market.”111
First, Congress incentivized innovator companies by creating a process that could extend patent
exclusivity by up to five years.112 Secondly, a generic
drug could gain approval before the patent’s expiration, enabling a generic maker to release the product
to market at the moment of expiration. 113 Further,
the Act enabled a generic maker to challenge the patent’s validity, presenting an opportunity for generic
drugs to reach the market even sooner.114 The Act
established a new ANDA process that also enabled
generic makers to market versions of drugs approved
after 1962.115
The Act also gave additional incentives for generic makers by granting a 180 day period of marketing exclusivity for the first generic maker that

111 Mylan Pharm., Inc. v. Thompson, 268 F.3d 1323, 1326
(Fed. Cir. 2001) (quoting Abbott Labs. v. Young, 920 F.2d 984,
991 (D.C. Cir. 1990) (Edwards, J., dissenting on other
grounds)).
112 Weiswasser & Danzis, supra note 94, at 590-91.
113 Clements, supra note 104, at 388.
114 Id.
115 Weiswasser & Danzis, supra note 94, at 593.
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successfully challenges a patent.116 However, the exclusivity to a first filer can create a bottleneck for generics; the FDA will not approve any subsequent
ANDAs pending the approval of the first ANDA, even
in the absence of litigation.117
C. The ANDA Process Under the
Hatch-Waxman Act
Under the Hatch-Waxman Act, the patents of
all drugs approved through the NDA are recorded in
their publication, Approved Drug Products with
Therapeutic Equivalence Evaluations, more commonly known as the “Orange Book.”118 Innovator
companies enjoy a period of “data exclusivity” for five
years in which a generic maker may not submit an
ANDA.119 After the data exclusivity period expires,
generic drugs are approved provided that the generic
is the “same and bioequivalent” to an approved patented drug.120 Applications must contain the following:
(1) a full list of articles used as components
of the drug,
(2) a full statement of the composition of
the drug,
(3) a full description of the methods used in,
and the facilities and controls used for
the manufacture, processing and packing of the drug,
(4) samples of the drug and components as
required by the FDA, and
Id. at 603.
Id.
118 Id. at 595.
119 21 U.S.C. § 355(c)(3)(E)(ii) (2012).
120 21 U.S.C. §§ 355(c)(3)(E)(iii), (j)(5)(F)(iii) (2012).
116
117
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(5) sample labeling.121

Generic makers must also file one of the following
certifications along with their ANDA:
(I)

that there are no patents listed in the
Orange Book for the drug (a “Paragraph I” certification);
(II) that the relevant patents have expired
(a “Paragraph II” certification);
(III) that the generic manufacturer will not
seek approval of the ANDA until after
the expiration of the relevant patent
(a “Paragraph III” certification); or
(IV) that such a patent is invalid or will
not be infringed by the manufacture,
use, or sale of the new generic drug for
which the ANDA is submitted (a “Paragraph IV” certification).122

Generally, the first three certifications do not
result in patent infringement litigation; the relevant
patents have either expired or the generic maker will
not release their product until after the patent’s expiration.123 However, a Paragraph IV certification
can be the opening salvo in litigation because the
certification puts an innovator company on notice
that their patent is being challenged. 124 Further, 35
U.S.C. § 271(e)(2) provides that conduct pursuant to
an ANDA submittal with the purpose of challenging

121 Weisswasser & Danzis, supra note 94, at 595 (quoting 21
U.S.C. § 355(b)(1)(B)-(F) (2012)) (internal quotations omitted).
122 Id. at 600 (citing 21 U.S.C. § 355(j)(2)(A)(vii) (2012)).
123 Id.
124 Id.
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a patent is considered infringement.125
The patent holder has forty five days to file
suit after being served notice that a Paragraph IV
certification has been filed.126 If the patent holder
does not file suit within the forty five day period the
ANDA may be approved and the patent holder forfeits their rights to a stay of FDA approval for the
generic.127 If the suit is filed within the forty five day
period, the FDA must stay the approval of the ANDA
for thirty months.128 The stay may be cut short by
the patent’s expiration, the patent’s invalidation by a
court ruling, or a finding that the patent was not infringed.129 The ANDA is approved upon a finding
that the patent is not valid or infringed. 130
The FDA grants a thirty month stay only
131
once.
An applicant will not be granted an additional stay for any subsequent Paragraph IV certifications.132 After the expiration of the stay, the innovator company may move for a preliminary injunction to enjoin the generic maker from releasing
their product.133
125 35 U.S.C. § 271(e)(2) (2012); Clements, supra note 104, at
389. But see 35 U.S.C. § 271(e)(1) (“It shall not be an act of
infringement to make, use, offer to sell, or sell within the
United States or import into the United States a patented
invention . . . solely for uses reasonably related to the
development and submission of information under a Federal
law which regulates the manufacture, use, or sale of drugs or
veterinary biological products.”).
126 Weiswasser & Danzis, supra note 94, at 600.
127 Id. at 601.
128 Id.
129 Id.
130 Id.
131 Id. at 602.
132 Id. at 603.
133 See id. at 601-03
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In the absence of a preliminary injunction, generic makers may attempt to release their product in
an “at-risk launch.”134 In such launches, the generic
maker can be liable for a significant amount of damages if the generic maker is later ruled to have infringed the patent.135 The threat of a large damage
award, which can exceed the expected revenues of a
generic drug, had kept at-risk launches at bay. 136
However, starting in 2007 generic makers have been
more aggressive in releasing product before the conclusion of litigation.137 Commentators have stressed
the importance of preliminary injunctions by noting
that preliminary injunctions have only been granted
in two instances following an at-risk launch.138
IV. SURVEY OF PRELIMINARY INJUNCTIONS IN
PHARMACEUTICAL PATENT INFRINGEMENT CASES
POST-EBAY IN THE DISTRICT OF NEW JERSEY
A Westlaw search reveals sixteen cases in the
District of New Jersey since the eBay decision in
2006 where an innovator company sought to enjoin a
generic maker from an at-risk launch.139 Prelimi134 Joseph M. O’Malley, Jr. et al., Failure to Launch,
INTELLECTUAL PROP. MAGAZINE at 30, 30 (Apr. 2011), available
at http://www.paulhastings.com/assets/publications/1877.pdf.
135 Id.
136 Id.
137 Id.
138 Id. at 31.
139 Hoffman-La Roche Inc. v. Apotex Inc., 496 Fed.App’x 46
(Fed. Cir. 2012) (denying preliminary injunction); Warner
Chilcott Labs. Ir. Ltd. v. Mylan Pharm. Inc., 451 Fed.App’x 935
(Fed. Cir. 2011) (appealing from the District of New Jersey,
holding that the trial court’s grant of preliminary injunction
was an abuse of discretion); Hoffman-La Roche Inc. v. Cobalt
Pharm. Inc., Nos. 07-4539(SRC)(MAS), 07-454(SRC)(MAS), 084054(SRC)(MAS), 2010 WL 4687839 (D.N.J. Nov. 10, 2010)
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nary injunctions were granted in seven instances. 140
Although the District of New Jersey has held in 2009
that eBay had abrogated the presumption of irreparable harm, a finding of likelihood of success on the
merits is still heavily linked to disposition of the sec(granting preliminary injunction); Albany Molecular Research,
Inc. v. Dr. Reddy’s Labs., Ltd., No. 09-4638(GEB-MCA), 2010
WL 2516465 (D.N.J. June 14, 2010) (granting preliminary
injunction); Sanofi-Aventis Deutschland GmbH v. Glenmark
Pharm. Inc., USA, No. 07-CV-5855(DMC), 2010 WL 2428561
(D.N.J. June 9, 2010) (denying preliminary injunction); King
Pharm., Inc. v. Sandoz, Inc., No. 08-5974(GEB-DEA), 2010 WL
1957640 (D.N.J. May 17, 2010); King Pharm., Inc. v.
Corepharma, LLC., No. 10-1878(GEB-DEA), 2010 WL 1850200
(D.N.J. May 7, 2010) (granting preliminary injunction);
Graceway Pharm., LLC v. Perrigo Co., 697 F.Supp.2d 600
(D.N.J. 2010) (denying preliminary injunction); Tyco Healthcare
Grp. LP v. Mut. Pharm. Co., No. 07-1299(SRC), 2009 WL
2422382 (D.N.J. Aug. 4, 2009) (denying preliminary injunction);
Ortho McNeil Pharm., Inc. v. Barr Labs., Inc., No. 034678(SRC), 2009 WL 2182665 (D.N.J. July 22, 2009) (granting
preliminary injunction); AstraZeneca LP v. Apotex, Inc., 623 F.
Supp.2d 579 (D.N.J. 2009), aff’d 633 F.3d 1042 (Fed. Cir. 2010)
(granting preliminary injunction); Everett Labs., Inc. v.
Breckenridge Pharm., Inc., 573 F. Supp.2d 855 (D.N.J. Aug. 28,
2008) (granting preliminary injunction); Eisai Co., Ltd. v. Teva
Pharm. USA, Inc., Nos. 05-5727(HAA)(ES), 07-5489(HAA)(ES),
2008 WL 1722098 (D.N.J. Mar. 28, 2008) (granting preliminary
injunction); Altana Pharma AG v. Teva Pharm. USA, Inc., 532
F. Supp.2d 666 (D.N.J. 2007) (denying preliminary injunction);
Novartis Pharm. Corp. v. Teva Pharm. USA, Inc. (Novartis I),
No. 05-CV-1887(DMC), 2007 WL 2669338 (D.N.J. Sept. 6, 2007)
(denying preliminary injunction); Novartis Corp. v. Teva
Pharm. USA, Inc. (Novartis II), Nos. 04-4473(HAA)(ES), 061130(HAA)(ES), 2007 WL 1695689 (D.N.J. June 11, 2007)
(denying preliminary injunction).
140 Cobalt Pharm., 2010 WL 4687839; Albany Molecular, 2010
WL 2516465; King Pharm., 2010 WL 1850200; Ortho McNeil,
2009 WL 2182665; AstraZeneca, 623 F. Supp 579; Everett Labs.,
573 F. Supp.2d 855; Eisai, 2008 WL 1722098.
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ond injunction factor.141
Hoffman-La Roche, Inc. v. Apotex, Inc., a recent case before the District of New Jersey, illustrates how the first preliminary injunction factor can
be dispositive.142 The drug at issue was Boniva, a
treatment for osteoporosis.143 U.S. Patent 4,927,814
(the “’814 patent”) was for one of the ingredients for
Boniva, while the other two patents, U.S. Patents
7,410,957 (the “’957 patent”) and 7,718,634 (the “’634
patent”) were for the method of treatment. 144 Hoffman-La Roche, referred to throughout the case as
simply Roche, sought to enjoin generic makers from
releasing their versions of Boniva after the expiration of the ’814 patent in March 2012. 145
The defendants in Hoffman-La Roche mounted
a vigorous challenge to the validity of the ’957 and
’634 patents.146 The defendants cited to numerous
studies, reports, and patents dating back to the late
1990s trying to establish that the industry was researching a weekly or monthly treatment for osteoporosis.147 The defendants argued that the ’957 and
141 See Ortho McNeil, 2009 WL 2182665, at *9-10 (D.N.J. July
22, 2009).
142 Hoffmann-La Roche Inc. v. Apotex Inc., Nos. 074417(SRC)(MAS), 08-3065(SRC)(MAS), 08-4053(SRC)(MAS),
10-6241(SRC)(MAS), 07-4661(SRC)(MAS), 08-4052(SRC)(MAS),
11-0579(SRC)(MAS), 07-4540(SRC)(MAS), 08-4054(SRC)(MAS),
10-6206(SRC)(MAS), 2012 WL 869572 (D.N.J. Mar. 14, 2012).
143 Id. at *1.
144 U.S. Patent No. 4,927,814 (filed July 9, 1987); U.S. Patent
No. 7,410,957 (filed May 6, 2003); U.S. Patent No. 7,718,634
(filed June 16, 2008).
145 Hoffman-La Roche v. Apotex, 2012 WL 869572, at *1.
146 For the obviousness standard, see Altana Pharma AG v.
Teva Pharm. USA, Inc., 532 F.Supp.2d 666, 674 (D.N.J. 2007)
aff’g, 566 F.3d 399 (Fed. Cir. 2009).
147 Hoffman-La Roche v. Apotex, 2012 WL 869572, at *3-6.
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’634 patents would have been obvious to a pharmaceutical researcher on account of the published studies.148 Moreover, Roche did not highlight “the ingenuity of the inventors,” which is unusual when defending patent validity.149
The court concluded that Roche did not establish a likelihood of success on the merits and denied
the motion for preliminary injunction.150 However,
the court declined to consider the other factors on basis of Roche failing to establish the first factor. 151
The court similarly considered only first factor in two
other instances where the plaintiff’s application for
preliminary injunction was denied.152
While seeking a preliminary injunction, innovator companies often argue that an entry of a generic competitor causes price erosion and loss of
market share.153 This, in turn, causes job losses, reduction of research opportunities for newer drugs,
and a loss of goodwill and brand equity. 154
The court in AstraZeneca v. Apotex, Inc., in
concluding that AstraZeneca had shown sufficient
evidence of irreparable harm, analyzed each of the
plaintiff’s arguments in depth.155 First, the court
concluded that the damages stemming from a loss of
market share and price erosion are not irreparable
Id. at *6.
Id. at *8.
150 Id. at *8-9.
151 Id.
152 King Pharm., Inc. v. Sandoz, Inc., No. 08-5974(GEB-DEA),
2010 WL 1957640, at *6 (D.N.J. May 17, 2010); Tyco Healthcare
Grp. LP v. Mut. Pharm. Co., No. 07-1299(SRC), 2009 WL
2422382, at *7 (D.N.J. Aug. 4, 2009).
153 AstraZeneca LP v. Apotex, Inc., 623 F. Supp.2d 579, 608
(D.N.J. 2009).
154 Id.
155 Id. at 608-14.
148
149
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because loss of sales and profits are generally calculable.156 Moreover, the resulting loss of research opportunity and funding is also calculable. 157
The court also found that Apotex’s at-risk
launch could cause irreparable harm through personnel layoffs.158 The court agreed that layoffs, while
commonplace in business, can cause a loss of morale
and productivity that cannot be calculated.159 Finally, the court concluded an at-risk launch can
cause market confusion.160 Moreover, AstraZeneca’s
reputation could suffer if customers, after lowering
prices to compete with Apotex, feel that the drug was
originally priced “at an unfairly high level.”161 Loss
of goodwill as an irreparable harm is a concept originally from trademark law that has been incorporated
into patent law.162
Despite a thorough analysis in AstraZeneca,
there is little consistency within the District of New
Jersey. In some instances, the court has held that a
loss of goodwill is too speculative to be an irreparable
harm.163 In other instances, the court has held that
156 However, the court found that the loss of future sales could
not be calculable due to a licensing agreement already in place
between AstraZeneca and another generic maker who had
promised not to release their generic until a later date. Thus,
in this instance, lost future sales and licensing revenue
constituted an irreparable harm. Id. at 608-11.
157 Id. at 613.
158 Id. at 612.
159 Id.
160 Id. at 613.
161 Id.
162 See Roy H. Wepner & Richard W. Ellis, The Federal
Circuit’s Presumptively Erroneous Presumption of Irreparable
Harm, 6 TUL. J. TECH. & INTELL. PROP. 147, 163-65 (2004).
163 Sanofi-Aventis, 2010 WL 2428561, at *17; Novartis I, 2007
WL 2669338, at *15.
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a potential loss of jobs is too speculative for irreparable harm at large companies, such as many of the innovator companies.164
The varied case law on how courts have evaluated irreparable harm in Hatch-Waxman actions validates Professor Chisum’s observations on irreparable harm determinations.165 The following cases
illustrate how the court usually finds irreparable
harm where it also finds a likelihood success from
the plaintiff.
In Novartis v. Teva Pharmaceuticals (Novartis
II). the court made a preliminary finding that
Novartis was unlikely to establish that Teva’s generic version of Lotrel infringed on Novartis’
patents.166 The court also found that Novartis failed
to establish Teva’s infringement under the doctrine
of equivalents.167
Novartis further argued that Teva’s at-risk
launch of generic Lotrel would cause irreparable
harm through “lost sales revenue, lost market share,
irreversible price erosion, lost business and growth
prospects, and lost research opportunities.”168 The
court said that economic loss estimates set forth by
Novartis seemed to go against their arguments for
irreparable harm.169 Further, the court posited that
any potential economic damages are calculable and
thus could “be reparable by money damages.” 170
Thus, the irreparable harm determination in
See Novartis II, 2007 WL 1695689, at *28.
See supra notes 35-36, 152, 156 and accompanying text.
166 See Novartis II, 2007 WL 1695689, at *24.
167 Id. at *25.
168 Id. at *26 (internal quotations omitted).
169 Id. at *27.
170 Id. (citing Nutrition 21 v. United States, 930 F.2d 867, 871
(Fed. Cir. 1991)).
164
165
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Novartis II is consistent with the definition in
Chisum’s treatise.171
However, the District of New Jersey found in a
subsequent case that an innovator company could
suffer irreparable harm while given similar economic
arguments. In Albany Molecular Research v. Dr.
Reddy’s Laboratories, a preliminary injunction was
sought to enjoin the defendant from an at-risk
launch172 of generic fexofenadine.173 Unlike the
Novartis court, the court in Albany Molecular found
that the plaintiff had demonstrated a likelihood of
success on the merits.174
Like in Novartis II, the plaintiff argued that
an at-risk launch would mean a loss of market share,
permanent price erosion and loss of brand equity. 175
Although the court noted that most of the harm suffered by the plaintiff would be monetary in nature
and calculable, it held that a “loss of goodwill associated with the brand” is considered an irreparable
harm.176 However, in a case decided just a few days
before Albany Molecular, a different judge in District
of New Jersey ruled that loss of goodwill was too
speculative for irreparable harm in Hatch-Waxman
litigation.177 In that case, the court declined to issue
See supra text accompanying note 35.
Albany Molecular, 2010 WL 2516465, at *1.
173 Fexofenadine is an allergy medication, notable brand
names include Allegra. NAT’L INST. OF HEALTH, Fexofenadine,
MEDLINEPLUS (last visited Feb. 19, 2014),
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a697035.ht
ml.
174 Albany Molecular, 2010 WL 2516465, at *9.
175 Id. at *11.
176 Id.
177 Sanofi-Aventis Deutschland GmbH v. Glenmark Pharm.
Inc., USA, No. 07-CV-5855(DMC), 2010 WL 2428561, at *17
(D.N.J. June 9, 2010).
171
172
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a preliminary injunction.178
In all seven instances where a preliminary injunction was granted by the District of New Jersey,
the court also found that the plaintiff had a likelihood of success on the merits.179 Likewise, in those
nine instances, the court also found that the plaintiff
had also established irreparable harm.180
Conversely, when the court declines to grant a preliminary injunction, it usually finds that the plaintiff
failed to establish a likelihood of success on the merits.181 Courts have refused to consider the remaining
factors once the plaintiff fails to establish the first
Id.
Hoffman-La Roche Inc. v. Cobalt Pharm. Inc., Nos. 074539(SRC)(MAS), 07-454(SRC)(MAS), 08-4054(SRC)(MAS),
2010 WL 4687839, at *1 (D.N.J. Nov. 10, 2010); King Pharm.,
Inc. v. Corepharma, LLC., No. 10-1878(GEB-DEA), 2010 WL
1850200, at *5 (D.N.J. May 7, 2010); AstraZeneca LP v. Apotex,
Inc., 623 F. Supp.2d 579, 614 (D.N.J. 2009), aff’d 633 F.3d 1042
(Fed. Cir. 2010); Ortho McNeil Pharm., Inc. v. Barr Labs., Inc.,
No. 03-4678(SRC), 2009 WL 2182665, at *11 (D.N.J. July 22,
2009); Everett Labs., Inc. v. Breckenridge Pharm., Inc., 573 F.
Supp.2d 855, 871 (D.N.J. Aug. 28, 2008); Eisai Co., Ltd. v. Teva
Pharm. USA, Inc., Nos. 05-5727(HAA)(ES), 07-5489(HAA)(ES),
2008 WL 1722098, at *13 (D.N.J. Mar. 28, 2008); see also
Warner Chilcott Labs. Ir. Ltd. v. Mylan Pharm. Inc., 451
Fed.App’x 935, 938 (Fed. Cir. 2011) (showing that although the
Federal Circuit reversed and vacated the injunction, the
District of New Jersey analyzed all four factors in favor of the
plaintiff).
180 See id.
181 Sanofi-Aventis, 2010 WL 2428561, at *17; Altana Pharma
AG v. Teva Pharm. USA, Inc., 532 F. Supp.2d 666, 684 (D.N.J.
2007); Novartis II, 2007 WL 1695689, at *28; Novartis I, 2007
WL 2669338, at *13; see also Graceway Pharm., LLC v. Perrigo
Co., 697 F.Supp.2d 600, 610 (D.N.J. 2010) (due to the innovator
company’s bad faith actions and the doctrine of laches the court
would have granted the preliminary injunction, found a
likelihood of success and irreparable harm).
178
179
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factor in some instances.182 When the courts consider all four factors, they have been consistent in
determining a lack of irreparable harm when declining injunctive relief.
CONCLUSIONS
The District of New Jersey has recognized that
eBay had abrogated the presumption of irreparable
harm in preliminary injunction determinations as
early as 2008.183 However, it seems that the presumption is alive and well in Hatch-Waxman actions,
in practice if not in name.184 It is clear that likelihood of success on the merits influences the irreparable harm determination.185 It is hard to envision
that the cases cited in Part IV would have been decided differently if eBay did not abrogate the presumption of irreparable harm in patent cases.
A. The Irreparable Harm Presumption Is
Not as Dead as the Bosch Court
Would Lead You to Believe
Ironically, the case that is considered the
death knell of the presumption of irreparable harm
also gives courts sufficient latitude to apply the presumption tacitly.186 The patent at issue in Robert
182 Apotex, 2012 WL 869572, at *9; King Pharm., Inc. v.
Sandoz, Inc., No. 08-5974(GEB-DEA), 2010 WL 1957640, at *6
(D.N.J. May 17, 2010); Tyco Healthcare Grp. LP v. Mut. Pharm.
Co., No. 07-1299(SRC), 2009 WL 2422382, at *7 (D.N.J. Aug. 4,
2009).
183 Everett Labs., 573 F.Supp.2d at 866.
184 See supra Part IV.
185 See supra text accompanying notes 166.
186 Jason Rantanen, Bosch v. Pylon: Jettisoning the
Presumption of Irreparable Harm in Injunction Relief,
PATENTLY-O (Oct. 12, 2011),
http://www.patentlyo.com/patent/2011/10/bosch-v-pylon-
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Bosch LLC v. Pylon Manufacturing Corporation was
for windshield wiper blades.187 Bosch is part of a
multinational conglomerate that manufactures and
sells a wide variety of goods including automotive
parts, industrial machinery, and consumer products,
such as power tools.188 Pylon is company based in
Florida that manufactures wiper blades under license from DuPont and Michelin.189 After obtaining
a favorable judgment at the district court, Bosch unsuccessfully sought a permanent injunction against
Pylon.190
On appeal, the Federal Circuit examined the
four injunction factors de novo.191 Acknowledging
that neither eBay nor its subsequent cases clearly
addressed the presumption of irreparable harm, the
Federal Circuit emphatically stated that “eBay jettisoned the presumption of irreparable harm as it applies to determining the appropriateness of injuncjettisoning-the-presumption-of-irreparable-harm-in-injunctionrelief.html.
187 Robert Bosch LLC v. Pylon Mfg. Corp., 659 F.3d 1142,
1145 (Fed. Cir. 2011).
188 Business Sectors and Divisions, BOSCH GROUP,
http://www.bosch.com/en/com/bosch_group/business_sectors_div
isions/business_sectors_divisions_2.php (last visited Feb. 21,
2014).
189 About Us, PYLON, http://www.pylonhq.com/company.html
(last visited Feb. 21, 2014).
190 Bosch, 659 F.3d at 1145.
191 Id. at 1148 (The permanent injunction factors are: “(1) that
it has suffered an irreparable injury; (2) that remedies available
at law, such a monetary damages are inadequate to compensate
for that injury; (3) that considering the balance of hardships
between the plaintiff and the defendant, a remedy in equity is
warranted; and (4) that the public interest would not be
disserved by a permanent injunction.”) (quoting eBay Inc. v.
MercExchange, L.L.C., 547 U.S. 388, 391 (2006)) (emphasis
added).
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tive relief.”192
The court noted that plaintiffs “can no longer
rely on presumptions or other short-cuts to support a
request for [injunctive relief].”193 However, the court
also enunciated that “the fundamental nature of patents as property rights grant[ ] the owner the right
to exclude.”194 The court noted that in cases of traditional patent infringement, courts should not act
from a “clean slate” and look to precedent in making
an injunction determination.195 Applying the four
factor analysis, the court found that Bosch had made
a showing of irreparable harm by, among other
things, establishing that Pylon had taken market
share through infringing product.196 In reversing the
trial court’s decision, at least one commentator has
noted that the new standard may not be much different from the old.197 The presumption of irreparable
harm may be dead, but Bosch allows courts to apply
the old presumption in traditional patent infringement cases without calling it by name.
B. Non-Practicing Entities, Patent Trolls, and
Non-Traditional Patent Infringement
Given their context, both eBay and Bosch were
decided correctly.
MercExchange did not make
commercial use of their patents; it sought to license
their patents after unsuccessfully attempting to open

Id. at 1149.
Id.
194 Id.
195 Id.
196 Id. at 1155.
197 Rantanen, supra note 186.
192
193
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on online marketplace.198 MercExchange is considered a non-practicing entity (NPE), which are sometimes pejoratively known as a patent troll. 199 Bosch,
on the other hand, is a global manufacturer that
spent approximately $5 billion in 2011 for research
and development.200
One of the more notable examples of a nonpracticing entity is Soverain Software. Soverain is
the holder of patents for online “shopping carts” used
in e-commerce.201 They do not manufacture products
of any kind nor do they sell goods over the internet or
otherwise.202 Instead, Soverain is known for initiating patent infringement suits and obtaining generous
settlements and licensing agreements.203 Due to
their litigious conduct, Soverain is widely known as a
patent troll. 204 In 2004, Soverain filed a patent in198 Brief for Respondent at 4, eBay Inc. v. MercExchange,
L.L.C., 547 U.S. 388 (2006) (No. 05-130), 2006 WL 622506, at *4
(March 10, 2006).
199 Jones, supra note 66, at 1040.
200 Bosch to Invest $10 Million to Support Local Higher
Education and Research Initiatives, BOSCH PRESS (May 19,
2011), http://www.bosch-press.com/tbwebdb/boschusa/modules/oragetblob.dll/BERN%20Investment%202011.pdf?
db=TBWebDB_rbna&item=TBWebDB_texpdf&id=466,1&dispo
=a (last visited Feb. 21, 2014).
201 Joe Mullin, How Newegg Crushed the “Shopping Cart”
Patent and Saved Online Retail, ARS TECHNICA (Jan. 27, 2013,
4:00 PM), http://arstechnica.com/tech-policy/2013/01/hownewegg-crushed-the-shopping-cart-patent-and-saved-onlineretail/.
202 Id.
203 Id. Notably, the term “patent troll” was used a total of five
times in Mullin’s article.
204 See, e.g., Don Reisinger, Newegg Wins Key ‘Shopping Cart’
Lawsuit Against Patent Troll, CNET (Jan. 28, 2013, 9:52 AM),
http://news.cnet.com/8301-1023_3-57566195-93/newegg-winskey-shopping-cart-lawsuit-against-patent-troll/; Mike Masnick,
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fringement action against Amazon.com and The Gap
alleging infringements of patents for online payment
processing and shopping carts.205 Amazon.com later
settled the case days within the start of trial for $40
million.206
The Supreme Court was correct in eBay to abrogate the presumption of irreparable harm. By
placing the burden of proof on the plaintiff to establish irreparable harm, litigation and the threat of a
permanent injunction cannot be used to force a settlement or as leverage in licensing negotiations, especially in cases where the patent holder is an NPE.
C. Differences Between NPEs and the
Pharmaceutical Companies and Why Congress
Should Amend the Hatch-Waxman Act to Allow
for the Irreparable Harm Presumption
Today, it is possible to be an NPE and own a
significant amount of patents, especially those related to information technology and internet applications. Instagram is a free photo sharing app for
Internet enabled smartphones.207 By the time Instagram was acquired by Facebook in 2012, it held
around eight hundred patents.208 Industry experts
Newegg’s ‘Screw Patent Trolls!’ Strategy Leads to Victory,
TECHDIRT (Jan. 28, 2013, 12:48 PM), .
205 Dawn Kawamoto, Amazon Pays $40 Million to Settle
Patent Dispute, ZDNET (Aug. 11, 2005, 9:11 PM),
http://www.zdnet.com/news/amazon-pays-40-million-to-settlepatent-dispute/144171.
206 Id.
207 FAQ, INSTAGRAM, http://instagram.com/about/faq/ (last
visited Mar. 2, 2013).
208 Tyler Kingkade, What Would $1 Billion Buy You Besides
Instagram & 800 Patents?, HUFFINGTON POST (Apr. 11, 2012,
1:46 PM), http://www.huffingtonpost.com/2012/04/11/1-billionwould-buy-you_n_1417712.html.
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have valuated the labor costs of developing an app
similar to Instagram at under $200,000. 209 Even
considering costs for filing patents, it does not take a
significant investment to create an NPE, sit on a
stable of patents, and make money purely through
licensing. As mentioned before, developing a new
drug can cost upwards of $800 million.210 Although
pharmaceutical companies can negotiate licensing
agreements, innovator companies will try to recoup
their substantial investment by releasing product to
the market themselves.
Moreover, “patent trolling” in the pharmaceutical industry is unlikely due to the nature of research.
Unlike information technology patents,
which may be vague, pharmaceutical patents are for
a thoroughly researched chemical.211 Further, the
research behind pharmaceutical patents is also protected by the Hatch-Waxman Act’s data exclusivity
period.212 Thus, pharmaceutical patent infringement
is almost always between two producing entities.
D. Moving Forward
While the Federal Circuit has made clear in
Bosch that the irreparable harm presumption is no
more, courts have the latitude to conclude similarly
209 Andres Garzon, The Correct Price for $1-Billion-Instagram
is $175,500, PRICETAG (Apr. 23, 2012),
http://pricetaghq.com/blog/correct-price-1-billioninstagram#sthash.KkIMBklN.dpuf; see also Roy Chomko, The
Real Cost of Developing an App, MANUFACTURING.NET (July 30,
2012, 11:50 AM),
http://www.manufacturing.net/articles/2012/07/the-real-cost-ofdeveloping-an-app.
210 See supra text accompanying note 9.
211 Stu Hutson, Pharma “Patent Trolls” Remain Mostly the
Stuff of Myth, 15 NATURE MEDICINE 1240 (2009).
212 Id.; see also supra text accompanying note 119.

69

PACE INTELL. PROP. SPORTS & ENT. LAW FORUM Vol. 4.1 (2014)

Reports of Its Death Are Greatly Exaggerated

as if the presumption still applies.213 Latitude is not
a certainty and different jurisdictions or even judges
may conclude differently for the irreparable harm
factor while adhering to the holding in Bosch. As
discussed earlier in this Article, the rulings of Federal courts in New Jersey in Hatch-Waxman actions
are consistent with the irreparable harm presumption, even if they decline to apply it.214 However, the
same cannot be said of other jurisdictions.
A lack of certainty can lead to forum shop215
ping.
Knowing that a patent infringement suit
may take much longer than a 30 month stay, innovator companies will try to file suit in a jurisdiction
where the first two preliminary injunction factors
have not been decoupled.216 This problem can be
solved by amending the Hatch-Waxman Act to give
courts the power to apply the irreparable harm presumption. Firstly, courts can apply tests or presumptions outside of the four factors with legislative
authorization.217 Secondly, applying the irreparable
harm presumption is consistent with the legislative
aims of the Act by strengthening pharmaceutical paSee supra Conclusion, Section A.
See supra Part IV.
215 See Ronald T. Coleman, Jr. et al., Applicability of the
Presumption of Irreparable Harm After eBay, 32 FRANCHISE
L.J. 3, 10 (2012) (“Perhaps most important, know your
jurisdiction. If a plaintiff has a choice as to where to bring a
lawsuit, look for a jurisdiction that continues to apply (or at
least has not foreclosed) the presumption of irreparable harm in
that kind of case. A potential defendant sometimes can exercise
forum selection as well by initiating a declaratory judgment
action in a forum that has applied eBay and demands proof of
irreparable harm.”).
216 See id.
217 See eBay, Inc. v. MercExchange, L.L.C., 547 U.S. 388, 39192 (2006).
213
214
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tent protections.
In conclusion, the presumption of irreparable
harm is still alive in Hatch-Waxman actions despite
reports to the contrary in eBay and Bosch. The tacit
application of the presumption is compatible with
current law because most instances of pharmaceutical patent infringement are considered to be “traditional.” Due to the immense costs of research and
clinical trials, pharmaceutical patents have enjoyed
heightened protection.
Amending the HatchWaxman Act to allow for the presumption would be
consistent with its original intent. However, even
without legislative action, eBay and Bosch do not
fundamentally change the outcomes of preliminary
injunction motions in Hatch-Waxman cases.
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